Granza Bio
ActiveReprogramming Immunity for Target-Specific Medicines
This company has previously operated under “Zyme Therapeutics”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Founders · 2
Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.
Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford
Related startups
Genetically engineered viruses that teach your immune system to kill…
We teach your immune system to attack and cure cancer
